Application No. 09/786,435
Filed: March 20, 2001
TC Art Unit: 1645
Confirmation No.: 1324

AMENDMENT TO THE CLAIMS

1. (Currently Amended) A method for inhibiting the biological activity of transforming growth factor β on ~~predamaged~~ damaged neurons in cerebral disorders, said method comprising the steps of:

providing a patient having ~~predamaged~~ damaged neurons, said damaged neurons resulting from a cerebral disorder, wherein said cerebral disorder is not intentionally induced; and

treating said ~~predamaged~~ damaged neurons in said patient with a compound that inhibits the biological activity of TGF-β on said ~~predamaged~~ damaged neurons.

2. (Canceled)

3. (Canceled)

4. (Canceled)

5. (Currently Amended) A pharmaceutical composition comprising, in pharmaceutically effective amounts, a first compound ~~capable of substantially~~ inhibiting the biological activity of TGF-β on ~~predamaged~~ damaged neurons caused by cerebral disorders, wherein said cerebral disorder is not intentionally induced, and a second compound for disintegrating blood clots, wherein said first and second compounds are formulated in a pharmaceutically acceptable carrier.

6. (Original) The pharmaceutical composition according to claim 5, wherein said compound is an antibody directed to TGF-β or a compound having the binding site of a TGF-β receptor.

7. (Original) The pharmaceutical composition according to claim 5, wherein said compound is an antibody directed to TGF-β or a compound having the binding site of a TGF-β receptor.

8. (Original) The pharmaceutical composition according to claim 5, wherein said second compound is selected from the group consisting of urokinase and tissue plasminogen activator.

9. (Canceled)

10. (Canceled)

11. (Previously Presented) The pharmaceutical composition according to claim 6, wherein said compound is an antibody directed to TGF-β or a compound having the binding site of a TGF-β receptor.

12. (Previously Presented) The pharmaceutical composition according to claim 6, wherein said second compound is selected from the group consisting of urokinase and tissue plasminogen activator.

13. (Previously Presented) The pharmaceutical composition according to claim 12, wherein said second compound is selected

from the group consisting of urokinase and tissue plasminogen activator.

14. (Currently Amended) The method of claim 1, wherein said compound inhibiting the biological activity of TGF-β is selected from the group consisting of (1) an antibody to TGF-β, (2) an antagonist to TGF-β, and (3) a compound ~~capable of~~ altering TGF-β.

15. (Currently Amended) The method of claim 14, wherein said compound is selected from the group consisting of TGFG-β inhibitors, compounds having the binding site of a TGF-β receptor, and TGF-β RII/Fc chimeric protein.

16. (Previously Presented) The method of claim 1, wherein said method further comprises treating said patient with a second compound for disintegrating blood clots.

17. (Currently Amended) The method of claim 16, wherein said second compound is selected from the group consisting of urokinase, thrombin and tissue plasminogen activator.

18. (Previously Presented) The method of claim 1, wherein said compound is administered intravenously, orally or intracerebrally.